About: Calanolide A

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Calanolide A is an experimental non-nucleoside reverse transcriptase inhibitor (NNRTI). This compound was extracted from the tree Calophyllum lanigerum, of variety austrocoriaceum, in Lundu, Malaysian state of Sarawak in 1992 by United States National Cancer Institute (NCI). Due to rarity of the raw materials and low yield of the active ingredient, total synthesis of the compound was devised in 1996. For the same reason, its sister compound (-)-Calanolide B (also known as Costatolide) have been tauted as replacement. As a result of the discovery of Calanolide A, Sarawak Medichem pharmaceuticals company was established as a joint venture between US-based MediChem Research Inc and Craun Research Sdn Bhd, a company owned by the Sarawak state government. In 2006, Craun Research acquired Sarawa

thumbnail
Property Value
dbo:abstract
  • Calanolide A is an experimental non-nucleoside reverse transcriptase inhibitor (NNRTI). This compound was extracted from the tree Calophyllum lanigerum, of variety austrocoriaceum, in Lundu, Malaysian state of Sarawak in 1992 by United States National Cancer Institute (NCI). Due to rarity of the raw materials and low yield of the active ingredient, total synthesis of the compound was devised in 1996. For the same reason, its sister compound (-)-Calanolide B (also known as Costatolide) have been tauted as replacement. As a result of the discovery of Calanolide A, Sarawak Medichem pharmaceuticals company was established as a joint venture between US-based MediChem Research Inc and Craun Research Sdn Bhd, a company owned by the Sarawak state government. In 2006, Craun Research acquired Sarawak MediChem. In 2016, Craun Research announced the completion of Phase I clinical trials for Calanolide A. (en)
dbo:casNumber
  • 142632-32-4
dbo:chEMBL
  • 267447
dbo:fdaUniiCode
  • S5A9TQN46W
dbo:pubchem
  • 64972
dbo:thumbnail
dbo:wikiPageID
  • 14562897 (xsd:integer)
dbo:wikiPageLength
  • 21159 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1123116789 (xsd:integer)
dbo:wikiPageWikiLink
dbp:atcPrefix
  • none (en)
dbp:c
  • 22 (xsd:integer)
dbp:casNumber
  • 142632 (xsd:integer)
dbp:chembl
  • 267447 (xsd:integer)
dbp:chemspiderid
  • 58497 (xsd:integer)
dbp:h
  • 26 (xsd:integer)
dbp:iupacName
  • 2 (xsd:integer)
  • 12 (xsd:integer)
  • -[10R,11S,12S]-10,11-trans-dihydro- (en)
dbp:metabolism
  • Hepatic (en)
dbp:o
  • 5 (xsd:integer)
dbp:proteinBound
  • >97% (en)
dbp:pubchem
  • 64972 (xsd:integer)
dbp:smiles
  • O=C/4Oc2c\CCCC (en)
dbp:stdinchi
  • 1 (xsd:integer)
dbp:stdinchikey
  • NIDRYBLTWYFCFV-FMTVUPSXSA-N (en)
dbp:unii
  • S5A9TQN46W (en)
dbp:wikiPageUsesTemplate
dcterms:subject
gold:hypernym
rdf:type
rdfs:comment
  • Calanolide A is an experimental non-nucleoside reverse transcriptase inhibitor (NNRTI). This compound was extracted from the tree Calophyllum lanigerum, of variety austrocoriaceum, in Lundu, Malaysian state of Sarawak in 1992 by United States National Cancer Institute (NCI). Due to rarity of the raw materials and low yield of the active ingredient, total synthesis of the compound was devised in 1996. For the same reason, its sister compound (-)-Calanolide B (also known as Costatolide) have been tauted as replacement. As a result of the discovery of Calanolide A, Sarawak Medichem pharmaceuticals company was established as a joint venture between US-based MediChem Research Inc and Craun Research Sdn Bhd, a company owned by the Sarawak state government. In 2006, Craun Research acquired Sarawa (en)
rdfs:label
  • Calanolide A (en)
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License